The report notes that separate UK regulations “could impose extra costs of £45,000 for each new product released, making the UK an unattractive market for new and innovative medicines.” But the call for continued membership in the EMA, in some form, has been echoed by other UK officials. Some experts have said the relationship between the UK’s MHRA and EMA could mirror the way in which Switzerland cooperates with the EMA. While acknowledging the need for EMA’s headquarters to move to Amsterdam, the committee said it recommends that as part of a new association with the EMA, the UK government should seek to retain a presence for EMA jobs and facilities in the UK. Rachel Reeves, chair of the committee, said in a statement: “The Government’s own analysis identifies pharmaceuticals as the sector for which UK/EU market access is the most important given the industry is reliant on friction-free border movement for their products. Any delays at the border faced by short-life pharmaceuticals for emergency treatments would have a hugely detrimental impact on patients.” More Information On RAPS